BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 13129633)

  • 1. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
    Lamb DS; Denham JW; Mameghan H; Joseph D; Turner S; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Kovacev O; Robertson R; Francis L; Christie D; Spry NA; Tai KH; Wynne C; Duchesne G
    Radiother Oncol; 2003 Sep; 68(3):255-67. PubMed ID: 13129633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
    Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
    Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
    Pilepich MV; Winter K; John MJ; Mesic JB; Sause W; Rubin P; Lawton C; Machtay M; Grignon D
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1243-52. PubMed ID: 11483335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
    Fair WR; Cookson MS; Stroumbakis N; Cohen D; Aprikian AG; Wang Y; Russo P; Soloway SM; Sogani P; Sheinfeld J; Herr H; Dalgabni G; Begg CB; Heston WD; Reuter VE
    Urology; 1997 Mar; 49(3A Suppl):46-55. PubMed ID: 9123736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
    Denham JW; Steigler A; Lamb DS; Joseph D; Mameghan H; Turner S; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Christie D; Spry NA; Tai KH; Wynne C; Duchesne G; Kovacev O; D'Este C;
    Lancet Oncol; 2005 Nov; 6(11):841-50. PubMed ID: 16257791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
    Lawton CAF; Lin X; Hanks GE; Lepor H; Grignon DJ; Brereton HD; Bedi M; Rosenthal SA; Zeitzer KL; Venkatesan VM; Horwitz EM; Pisansky TM; Kim H; Parliament MB; Rabinovitch R; Roach M; Kwok Y; Dignam JJ; Sandler HM
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):296-303. PubMed ID: 28463149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.
    Shipley WU; Lu JD; Pilepich MV; Heydon K; Roach M; Wolkov HB; Sause WT; Rubin P; Lawton CA; Machtay M
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1302-10. PubMed ID: 12459350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza RodrĂ­guez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; VillĂ  S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.
    Hanks GE; Pajak TF; Porter A; Grignon D; Brereton H; Venkatesan V; Horwitz EM; Lawton C; Rosenthal SA; Sandler HM; Shipley WU;
    J Clin Oncol; 2003 Nov; 21(21):3972-8. PubMed ID: 14581419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation.
    Christie D; Denham J; Steigler A; Lamb D; Turner S; Mameghan H; Joseph D; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Spry NA; Tai KH; Wynne C; Duchesne G; Kovacev O; Francis L; Kramar A; D'Este C; Bill D
    Radiother Oncol; 2005 Nov; 77(2):117-25. PubMed ID: 16271786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
    Efstathiou JA; Bae K; Shipley WU; Hanks GE; Pilepich MV; Sandler HM; Smith MR
    Eur Urol; 2008 Oct; 54(4):816-23. PubMed ID: 18243498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer.
    Schulman CC; Debruyne FM; Forster G; Selvaggi FP; Zlotta AR; Witjes WP
    Eur Urol; 2000 Dec; 38(6):706-13. PubMed ID: 11111188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
    Soloway MS; Schellhammer P; Sharifi R; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Eur Urol; 1996; 29 Suppl 2():105-9. PubMed ID: 8717471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.
    Pilepich MV; Krall JM; al-Sarraf M; John MJ; Doggett RL; Sause WT; Lawton CA; Abrams RA; Rotman M; Rubin P
    Urology; 1995 Apr; 45(4):616-23. PubMed ID: 7716842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.
    Shipley WU; Desilvio M; Pilepich MV; Roach M; Wolkov HB; Sause WT; Rubin P; Lawton CA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1162-7. PubMed ID: 16427211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.
    Lawton CA; Winter K; Murray K; Machtay M; Mesic JB; Hanks GE; Coughlin CT; Pilepich MV
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):937-46. PubMed ID: 11240234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A quality assurance audit: phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01).
    Steigler A; Mameghan H; Lamb D; Joseph D; Matthews J; Franklin I; Turner S; Spry N; Poulsen M; North J; Kovacev O; Denham J
    Australas Radiol; 2000 Feb; 44(1):65-71. PubMed ID: 10761262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.
    Mason M; Maldonado Pijoan X; Steidle C; Guerif S; Wiegel T; van der Meulen E; Bergqvist PB; Khoo V
    Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):190-6. PubMed ID: 23257248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.